drugset / Trial / NCT07165951
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Phase 3
Recruiting
566 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment
Summary
This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib hydrochloride capsules combined with chemotherapy, compared to placebo combined with chemotherapy.
Timeline
- Start
- 2025-12-02
- Primary completion
- 2028-05
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2868 | Protein / enzyme biologic | — | — |
| Background | Catequentinib | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |